SOLICITATION NOTICE
B -- Bioanalysis Testing Services
- Notice Date
- 9/8/2015
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA(SSSA)-2015-CSS-152
- Archive Date
- 10/6/2015
- Point of Contact
- Rodney E. Brooks, Phone: 3014020751
- E-Mail Address
-
rodney.brooks@nih.gov
(rodney.brooks@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Combined Synopsis / Solicitation Title: Bioanalysis Testing Services (i) This is a combined synopsis/solicitation for commercial services prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is HHS-NIH-NIDA (SSSA)-2015-CSS-152 and the solicitation is issued as a request for proposal (RFP). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; FAR Subpart 13.5-Test Program for Certain Commercial Items; and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-83, dated August 5, 2015. (iv) A notice regarding any set-aside restrictions, the associated NAICS code 541380-Testing Laboratories, Size Standard $14.0 (v) Background The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people's health and save lives. The National Institute on Aging (NIA), one of the 27 Institutes and Centers of NIH, leads the federal government in conducting and supporting research on aging and the health and well-being of older people. The Institute seeks to understand the nature of aging and the aging process, and diseases and conditions associated with growing older, in order to extend the healthy, active years of life. In 1974, Congress granted authority to form NIA to provide leadership in aging research, training, health information dissemination, and other programs relevant to aging and older people. Subsequent amendments to this legislation designated NIA as the primary Federal agency on Alzheimer's disease research. The National Institute on Aging's Baltimore Longitudinal Study of Aging (BLSA) is America's longest-running scientific study of human aging. It began in 1958, when gerontology-the study of aging-was still very much in its infancy. It is one of the longest ongoing longitudinal studies of aging in the world. The goal of the study is to answer the big question "What is aging?" The scope of this question has evolved over the years. At its birth, the BLSA focused on the physical and cognitive changes associated with normal aging, free of disease. The study later began to address the interrelationship between disease and age-related changes, looking at their combined effect on physical and cognitive function. Today, the question also extends to exceptional aging, targeting rare individuals who go through most of their life, well into their eighties, with no health problems. The BLSA continues to pursue the following objectives: (1) Describe longitudinal physical and cognitive changes that define aging; (2) Identify genetic, physical, behavioral, and environmental factors that affect the rate of change in these traits; and (3) Understand the interrelationship between aging and chronic disease and other conditions, and their independent and joint impact on age-related decline. Purpose and Objectives: The purpose of this requirement is to purchase bio-analysis testing services to perform metabolomics assays on human tissue samples from the National Institute on Aging's (NIA) Baltimore Longitudinal Study of Aging (BLSA). Scope of Work: Independently and not as an agent of the Federal Government, the contractor shall perform quantitative targeted metabolomics assays on human serum samples from the Baltimore Longitudinal Study of Aging participants. The contractor shall: (1) Perform quantitative targeted metabolomics assays on approximately 800 human serum samples from non-demented older individuals and converters to AD to measure the concentrations of small metabolites in the following classes: (a) Phosphatidylcholines; (b) Phosphatidylserines; (c) Phosphatidylglycerols; (d) Phosphatidyethanolamines; (e) Sphingomyelins; (f) Ceramides; (g) Eicosanoids; (h) Prostaglandins; and (i) Oxysterols. These samples will come from the Baltimore Longitudinal Study of Aging (BLSA; N=400) and the Age Gene/Environment Susceptibility-Reykjavik Study (AGES-RS; N=400). (2) Perform quantitative targeted metabolomics assays on a random sample of approximately 400 human serum samples from non-demented older individuals in the Age Gene/Environment Susceptibility-Reykjavik Study (AGES-RS; N=400) to assay the following classes of small metabolites: (a) Amino Acids, Acylcarnitines, Lipids, Hexoses, Biogenic Amines & Polyamines; (b) Phosphatidylcholines; (c) Phosphatidylserines; (d) Phosphatidylglycerols; (e) Phosphatidyethanolamines; (f) Sphingomyelins; (g) Ceramides; (h) Eicosanoids; (i) Prostaglandins; and (j) Oxysterols. (3) Perform quantitative targeted metabolomics assays on approximately 200 human cerebrospinal fluid (CSF) samples from participants in the BIOCARD study to assay the following classes of small metabolites: (a) Amino Acids, Acylcarnitines, Lipids, Hexoses, Biogenic Amines & Polyamines; (b) Phosphatidylcholines; (c) Phosphatidylserines; (d) Phosphatidylglycerols; (e) Phosphatidyethanolamines; (f) Sphingomyelins; (g) Ceramides; (h) Eicosanoids; (i) Prostaglandins; and (j) Oxysterols. (vi) The period of performance is 12-months from September 28, 2015 through September 27, 2016. (vii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (viii) The provision at FAR clause 52.212-2, Evaluation - Commercial Items applies to this acquisition. Selection of an Offeror for award will be on the basis of lowest price technically acceptable quote meeting the government's requirement specified herein and evidence of successful past performance. Offeror(s) cost/price proposal will be evaluated for reasonableness. For a price to be reasonable, it must represent a price to the Government that a prudent person would pay when consideration is given to prices in the market. Normally, price reasonableness is established through adequate price competition, but may also be determined through cost and price analysis techniques as described in FAR 15.404. The price quoted will be evaluated taking into consideration any price reductions. A best value analysis will be performed taking into consideration the results of the technical evaluation and price evaluation. The Government will award a purchase order resulting from this solicitation on the basis of best value, technical factors and price considered. Technical factors together shall be considered more important than price. (ix) The provision at FAR clause 52.212-3, Offeror Representations and Certifications - Commercial Items, applies to this acquisition. (x) FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. An addendum to FAR clause 52.212-4, Contract Terms and Conditions-Commercial Items applies to this acquisition. (xi) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. FAR 52.227-14 Rights in Data-General, (DEC 2007), applies to this acquisition. (xii) The Defense Priorities and Allocations System (DPAS) are not applicable to this (xiii) Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. In addition, responses must include clear and convincing evidence of the offeror's capability of fulfilling the requirement as it relates to the technical evaluation criteria and a price proposal. The response should be practical, clear, and concise; should use quantitative terms whenever possible; should avoid qualitative adjectives; and should comprehensively address the requirements of this solicitation. Assumptions, conditions, or exceptions with any of the terms and conditions of this solicitation must be noted. If not noted, the Government will assume that no assumptions, conditions, or exceptions are made and the offeror agrees to comply with all of the terms and conditions as set forth in the solicitation. Information requested herein must be furnished in writing fully and completely in compliance with the solicitation. The information requested and the manner of submittal is essential to permit prompt evaluation of all offers on a fair and uniform basis. Simple statements of compliance (i.e., "understood"; "will comply") or phrases such as "standard procedures will be used" or "well known techniques will be utilized" and other generalities, without the detailed description of how compliance will be met, may not be considered sufficient evidence that the proposal can technically meet the project requirements. Accordingly, any response in which material information requested is not furnished or where indirect or incomplete answers or information are provided may be considered not acceptable. Offerors must submit an itemized price quote shall include: (1) unit price for quantitative targeted metabolomics assays on non-demented older individuals human serum samples; quantity 800; (2) unit price for quantitative targeted metabolomics assays on non-demented older individuals human serum samples; quantity 400; and (3) unit price for quantitative targeted metabolomics assays on cerebrospinal fluid (CSF) samples; quantity 200. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All questions regarding this combined synopsis/solicitation must be received in this office by 8:00AM (EST) on September 10, 2015. Offers must be received electronically by 12:00 PM (EST) on September 21, 2015. Facsimile submissions are not authorized and collect calls will not be accepted. Submit offers to: Rodney Brooks, Contract Specialist at rodney.brooks@nih.gov and NIDASSSAPurchaseRequ@mail.nih.gov Please reference the solicitation number HHS-NIH-NIDA-(SSSA)-CSS-15-152 on your offer. Requests for information concerning this requirement are to be addressed to Rodney Brooks via e-mail only to rodney.brooks@nih.gov prior to the closing date for questions.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA(SSSA)-2015-CSS-152 /listing.html)
- Record
- SN03875382-W 20150910/150908235327-baf51ed980f9e41eff6a6545c68a47c8 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |